Consolidated Statement of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenues:
Clinical treatment programs - US	$ 21	$ 33	$ 85	$ 85
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]	AIM:ClinicalTreatmentProgramsUSMember	AIM:ClinicalTreatmentProgramsUSMember	AIM:ClinicalTreatmentProgramsUSMember	AIM:ClinicalTreatmentProgramsUSMember
Costs and Expenses:
Production costs		$ 157		$ 674
Research and development	1,372	2,006	4,883	4,749
General and administrative	5,170	1,799	9,569	6,055
Total Costs and Expenses	6,542	3,962	14,452	11,478
Operating loss	(6,521)	(3,929)	(14,367)	(11,393)
Loss on investments	(365)		(1,769)
Interest and other income, net	172	(20)	296	100
Interest expense and other finance costs				(67)
Extinguishment of financing obligation and note payable				(2,701)
Gain on sale of fixed assets				216
Redeemable warrants valuation adjustment	1	51	35	22
Gain from sale of income tax operating losses	328	72	749	542
Net Loss	(6,385)	(3,826)	(15,056)	(13,281)
Other comprehensive (loss), net of tax
Reclassification adjustment for realized investment loss		101		126
Change in unrealized loss on marketable securities available for sale		(104)		(329)
Comprehensive loss	$ (6,385)	$ (3,829)	$ (15,056)	$ (13,484)
Basic and diluted loss per share	$ (0.13)	$ (0.08)	$ (0.31)	$ (0.28)
Weighted average shares outstanding basic and diluted	48,079,210	47,846,074	48,036,559	47,156,158